O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150

医学 索拉非尼 阿替唑单抗 内科学 贝伐单抗 肝细胞癌 肿瘤科 总体生存率 生活质量(医疗保健) 无进展生存期 扩展访问 不利影响 伦瓦提尼 胃肠病学 癌症 化疗 无容量 免疫疗法 护理部
作者
D. Li,Han Chong Toh,Philippe Merle,Kaoru Tsuchiya,Sairy Hernandez,Hui Shao,Sohail Mulla,Beiying Ding,Masatoshi Kudo
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:31: 234-234 被引量:11
标识
DOI:10.1016/j.annonc.2020.04.061
摘要

Data regarding the efficacy and safety of systemic therapies in older adults with hepatocellular carcinoma (HCC) are limited. In the phase III IMbrave150 trial, atezolizumab + bevacizumab was associated with statistically significant and clinically meaningful improvements in overall survival (OS; HR, 0.58; 95% CI: 0.42, 0.79) and progression-free survival (PFS; HR, 0.59; 95% CI: 0.47, 0.76) as well as clinically meaningful delays in deterioration of patient-reported functioning and quality of life (QoL) vs sorafenib in patients with unresectable HCC who had not received prior systemic therapy (Cheng, ESMO Asia, 2019). Here, we report exploratory subgroup analyses of the efficacy, safety and patient-reported outcome (PRO) results for older adults enrolled in IMbrave150. IMbrave150 randomized 501 systemic treatment (tx)–naïve patients with unresectable HCC. Patients were randomized 2:1 to receive either atezolizumab 1200 mg IV q3w + bevacizumab 15 mg/kg IV q3w or sorafenib 400 mg BID until unacceptable toxicity or loss of clinical benefit per investigator. Co-primary endpoints were OS and PFS by independent review facility (IRF)-assessed RECIST 1.1. Objective response rate (ORR) per IRF-RECIST 1.1 and time to deterioration (TTD) in patient-reported physical functioning, role functioning and QoL per the EORTC QLQ-C30 questionnaire were pre-specified secondary endpoints. The exploratory older adult subgroup was defined to include those aged ≥ 65 years. In IMbrave150, 161 (48%) patients enrolled in the atezolizumab + bevacizumab arm and 91 (55%) in the sorafenib arm were aged ≥ 65 years. In these patients, the median OS was not reached with atezolizumab + bevacizumab vs 14.9 months with sorafenib (HR, 0.58; 95% CI: 0.36, 0.92). The median PFS was 7.7 months with atezolizumab + bevacizumab vs 4.8 months with sorafenib (HR, 0.63; 95% CI: 0.45, 0.89). ORRs were 26% with atezolizumab + bevacizumab vs 13% with sorafenib, with 7 and 0 patients achieving complete responses, respectively. TTD in physical functioning (HR, 0.48; 95% CI: 0.32, 0.73), role functioning (HR, 0.61; 95% CI: 0.40, 0.91) and QoL (HR, 0.71; 95% CI: 0.47, 1.07) were longer for patients receiving atezolizumab + bevacizumab vs sorafenib. In the atezolizumab + bevacizumab arm, 62 of 158 (39%) treated patients aged ≥ 65 years experienced a grade 3-4 treatment-related AE (TRAE) and 4 (3%) patients experienced a grade 5 TRAE, whereas 55 of 171 (32%) treated patients aged < 65 years experienced a grade 3-4 TRAE and 1 (1%) patient experienced a grade 5 TRAE. Exploratory analyses were also conducted with the subgroup of patients aged ≥ 70 years, showing similar results for efficacy, safety and PROs. Similar to the IMbrave150 ITT population, older adults with previously untreated, unresectable HCC derived a clinically meaningful benefit from atezolizumab + bevacizumab vs sorafenib. Additionally, treatment with atezolizumab + bevacizumab showed a delay in deterioration in patient-reported functioning and QoL vs sorafenib. Safety of atezolizumab + bevacizumab in adults ≥ 65 years old is generally consistent with the safety in younger patients, with no added risks or toxicities.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
迅速凝竹完成签到 ,获得积分10
1秒前
妮妮完成签到,获得积分10
2秒前
2秒前
哈哈哈完成签到,获得积分20
3秒前
快乐随心完成签到 ,获得积分10
4秒前
了一李完成签到 ,获得积分10
4秒前
fqk完成签到,获得积分10
4秒前
活泼新儿完成签到,获得积分10
4秒前
5秒前
老迟到的羊完成签到 ,获得积分10
5秒前
可爱的函函应助sl采纳,获得30
9秒前
CatC完成签到,获得积分10
9秒前
LIKO完成签到,获得积分10
9秒前
9秒前
9秒前
David发布了新的文献求助10
10秒前
10秒前
clock完成签到 ,获得积分10
10秒前
风中小懒虫完成签到,获得积分10
11秒前
cindy完成签到 ,获得积分10
12秒前
Tysonqu完成签到,获得积分10
12秒前
科研通AI2S应助Promise采纳,获得10
13秒前
14秒前
淡淡阁完成签到 ,获得积分10
14秒前
念念发布了新的文献求助10
14秒前
漂亮的秋天完成签到 ,获得积分10
16秒前
David完成签到,获得积分10
16秒前
Jason完成签到,获得积分10
16秒前
20秒前
21秒前
21秒前
YY完成签到,获得积分10
22秒前
调皮的凝旋完成签到,获得积分10
23秒前
23秒前
念念完成签到,获得积分20
24秒前
崔悦欣完成签到,获得积分10
26秒前
xiaosui完成签到 ,获得积分10
26秒前
夏初水莲洁完成签到,获得积分10
27秒前
Jasper应助小王采纳,获得10
27秒前
ZXH完成签到,获得积分10
28秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029